Compare Alcon AG (ALC) vs Chevron Corp (CVX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Chevron Corp — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Chevron Corp trades at $176.59 (market cap $346.56B). The key difference: Chevron Corp is far larger — about 10.6× Alcon AG's market cap, and Chevron Corp pays the higher dividend (4.09%). Which is the better fit depends on your goals.
| ALC | CVX | |
|---|---|---|
Market Cap | $32.69B | $346.56B |
Sector | Health | Energy |
52-Week High | $92.22 | $211.14 |
52-Week Low | $62.02 | $146.72 |
Enterprise Value | $36.28B | $386.66B |
Dividend Yield | 0.54% | 4.09% |
Volume | — | 9,807,834 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Chevron (CVX) trades at $175.91, up 4.65% today, with a bullish technical signal and strong analyst consensus. Recent earnings beat expectations, though revenue and net income have declined year-over-year. The company maintains solid cash flow and a $1.78 dividend, while pursuing growth via a $13.8B Argentina investment (Reuters, 2026-06-02).
CVX offers value through dividends and growth projects, but faces headwinds from falling profitability and oil price volatility. Analyst targets average $209, suggesting upside, yet execution risks and margin pressure warrant caution for investors seeking energy exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →
